ADC Therapeutics announced a strategic reorganization. This plan includes a 17% reduction in its global workforce. The company expects to save $10 million annually from these cuts. This follows recent safety concerns in a Zynlonta clinical trial. The reorganization aims to focus resources on the Zynlonta franchise.
https://www.fiercepharma.com/pharma/amid-safety-concerns-adc-therapeutics-plots-17-staff-cuts-push-resources-behind-lead-adc